Cutler Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Cutler Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1K	Sell	3,300 -10,300	-76%	-$433K	﹤0.01%	2161
2023 Q4	$107K	Buy	+13,600	New	+$391K	0.01%	1033
2023 Q1	–	Sell	-3,300	Closed	-$5K	–	4927
2022 Q4	$5K	Buy	3,300 +1,200	+57%	+$33.9K	﹤0.01%	3234
2022 Q3	$2K	Buy	+2,100	New	+$62.5K	﹤0.01%	4356
2022 Q2	–	Sell	-20,900	Closed	-$47K	–	5867
2022 Q1	$47K	Buy	20,900 +15,300	+273%	+$447K	﹤0.01%	2302
2021 Q4	$13K	Sell	5,600 -4,500	-45%	-$159K	﹤0.01%	3508
2021 Q3	$33K	Sell	10,100 -17,600	-64%	-$494K	﹤0.01%	2900
2021 Q2	$91K	Buy	+27,700	New	+$397K	﹤0.01%	1969

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cutler Group's CERE Position: Q1 2024 in Review

Cutler Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 6,600 shares — an estimated $277K sold.

Cutler Group first reported a position in CERE in Q2 2021 and held it in 8 quarters. The position peaked at $279K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

Cutler Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 6,600 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $277K.
Cutler Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Cutler Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $279K in Q4 2023.
210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.